CD80 and neoplasm: B7-1 molecule expression on tumor cells can elicit anti-tumor immunity at the induction phase [11], [12], [20], [21]; however, there has been no direct evidence to support the enhancement of anti-tumor immunity at the effector phase by B7-1.